SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 78 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $161,000 | -22.2% | 36,093 | -5.0% | 0.07% | -16.5% |
| Q2 2021 | $207,000 | +7.3% | 37,977 | +47.4% | 0.08% | +3.7% |
| Q1 2021 | $193,000 | -29.8% | 25,773 | +1.8% | 0.08% | -28.1% |
| Q4 2020 | $275,000 | -10.7% | 25,323 | -27.3% | 0.11% | -29.6% |
| Q3 2020 | $308,000 | -27.0% | 34,835 | -12.0% | 0.16% | -19.0% |
| Q2 2020 | $422,000 | -0.5% | 39,578 | +11.2% | 0.20% | +354.5% |
| Q3 2018 | $424,000 | -32.7% | 35,601 | -42.3% | 0.04% | -92.1% |
| Q2 2018 | $630,000 | – | 61,719 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC | 4,806,656 | $87,241,000 | 14.92% |
| Aisling Capital LLC | 908,565 | $16,490,000 | 3.89% |
| Foresite Capital Management III, LLC | 150,000 | $2,723,000 | 1.87% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,095,220 | $38,028,000 | 1.50% |
| Redmile Group, LLC | 946,182 | $15,058,000 | 1.44% |
| Casdin Capital, LLC | 50,000 | $908,000 | 0.90% |
| Eventide Asset Management | 150,000 | $2,723,000 | 0.17% |
| Weiss Multi-Strategy Advisers LLC | 45,857 | $832,000 | 0.06% |
| Baker Brothers Advisors | 204,465 | $3,711,000 | 0.04% |
| Alyeska Investment Group, L.P. | 70,000 | $1,271,000 | 0.01% |